Third Trademark Issued

(BUFFALO, NY) Apr. 1, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in vivo cellular data, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Trademark No. 6,687.149 for the CytoComm® trade name. This US trademark is the third issued to Efferent Labs®.

“This is another important addition to our property portfolio providing product and trade protection for our products” said Bill Rader, CEO of Efferent Labs, Inc.

The company has two additional registered trademarks, including the corporate name “Efferent Labs®” and company tag line “Merging life and data®”, with one more registered trademark pending.

About Efferent Labs
Efferent Labs, with operations in Buffalo, N.Y., is engaged in the development and commercialization of their CytoComm™ implantable biosensor for use in pre-clinical animal research. Their technology will lower costs associated with animal research by >20% and provide researchers with real-time data at the cellular level. The company is currently on track to commercialize their first biosensor platform, CytoComm™, in mid-2023.

Related Posts

Third Trademark Issued

(BUFFALO, NY) Apr. 1, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in

About Us

Efferent Labs offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.

 

Let’s Socialize

Popular Post